Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression

In this study we have surveyed by immunoblotting the protein levels of Cyclin D1, D2, D3 and their catalytic partners, Cdk4 and Cdk6 in normal and transformed human cells. We found that all these proteins were differentially expressed in diploid cells derived from different tissues, in contrast to Cyclin E, Cyclin A and Cdk2 which are ubiquitously expressed. D-type Cyclins were never dramatically overexpressed and often very poorly expressed in tumor cell lines when compared to the levels in their normal counterparts. In contrast, Cdk4 was expressed at high levels in several tumor cell lines and Cdk6 was ectopically expressed in two sarcoma lines, suggesting a possible involvement of these two Cdks in oncogenesis. Interestingly, low levels of Cyclin D1 and D3 proteins always correlated with functional inactivation of the retinoblastoma gene product (pRb). In cells displaying active pRb, Cyclin D1 was found associated with Cdk4 regardless of whether the p53 gene was wild-type or mutant. Microinjection during G1 of Cyclin D1 anti-sense cDNA or anti-Cyclin D1 antibody in these cells arrested the cell cycle in G1. In cells lacking pRb function, Cyclin D1 was dissociated from Cdk4. Microinjection during G1 of Cyclin D1 antisense cDNA or anti-Cyclin D1 antibody in these cells did not affect G1 progression. These results show that (i) in the absence of pRb, Cyclin D1 is expressed at low levels, is dissociated from Cdk4 and becomes dispensable in G1; (ii) Cyclin D1 needs to be associated with its catalytic subunit, Cdk4, to function as a positive regulator of G1 progression.

Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts

Cyclin D1 is a key regulator of the G1 phase of the cell cycle. Inhibition of cyclin D1 function results in cell cycle arrest, whereas unregulated expression of the protein accelerates G1. Cyclin D1 is localized to the nucleus during G1. We found that during repair DNA synthesis, subsequent to UV-induced DNA damage, G1 cells readily lost their cyclin D1 while the proliferating cell nuclear antigen (PCNA) tightly associated with nuclear structures. Microinjection of cyclin D1 antisense accelerated DNA repair, whereas overexpression of cyclin D1 prevented DNA repair and the relocation of PCNA after DNA damage. Coexpression of cyclin D1 with its primary catalytic subunit, Cdk4, or with Cdk2, also prevented repair. In contrast, coexpression of PCNA, which is also a cyclin D1-associated protein, restored the ability of cells to repair their DNA. Acute overexpression of cyclin D1 in fibroblasts prevented them from entering S phase. Again, these effects were abolished by coexpression of cyclin D1 together with PCNA, but not with Cdk4 or Cdk2. Altogether, these results indicate that down-regulation of cyclin D1 is necessary for PCNA relocation and repair DNA synthesis as well as for the start of DNA replication. Cyclin D1 appears to be an essential component of a G1-checkpoint.

Modulation of cyclin gene expression by adenovirus E1A in a cell line with E1A-dependent conditional proliferation

To investigate how adenovirus E1A controls cell proliferation, we have fused E1A to the hormone-binding domain of the human estrogen receptor (ER) and introduced the E1A-ER chimeric gene together with an activated ras gene into primary rat embryo fibroblasts. Cell lines derived from this transfection proliferate in an estrogen-dependent manner. Estrogen-dependent activation of E1A-ER led to a rapid induction of both cyclin E and cyclin A gene expression. In contrast, levels of cyclin D1 were strongly reduced by activation of E1A-ER. Similar changes in cyclin gene expression were observed when primary human fibroblasts were infected with wild-type adenovirus and when adenovirus E1A was stably expressed in NIH 3T3 cells. Our findings suggest that activation of cyclin A and E, but not D1, gene expression by E1A precedes and may be responsible for E1A-dependent cell proliferation. In contrast, we found that quantitative disruption of complexes between the E2F transcription factor and the retinoblastoma protein is not required for E1A-dependent S-phase entry.

Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines

Among the key cell cycle regulators, cyclin D1 has been implicated most strongly in oncogenesis. This G1 cyclin is a putative proto-oncogene whose clonal rearrangement and/or amplification and mRNA overexpression occurs in several types of human neoplasias. We have now raised a series of monoclonal antibodies to human cyclin D1 and analysed its regulation at the protein level in 40 human tumour cell lines. We found that 12 cell lines displayed low or undetectable cyclin D1 protein level, while the remaining lines accumulated the protein to a level comparable to, or moderately higher than, that of four normal diploid non-immortalized cell types. The cell cycle-dependent oscillation and subcellular localization of cyclin D1 were similar in both tumour and normal cells. The protein localized to the nucleus of G1 cells, and it was reduced to immunocytochemically undetectable level in DNA-replicating cells. At the functional level, microinjection and electroporation of anti-D1 antibodies revealed that in most tumour cell lines studied, including those with amplification at the cyclin D1 locus, this cyclin is essential for cell cycle progression in G1. Some tumours, however, seem to have evolved mechanism(s) that enable them to bypass the requirement for functional cyclin D1.

"In vitro" study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin

We have studied the soluble fragments obtained from bovine lens capsules after digestion by the cysteine proteinases cathepsins B, B-like and L. These proteinases liberated collagen IV, laminin and fibronectin fragments, as shown by immunoblotting. Sodium dodecyl sulfate treatment of digested capsules gave a soluble material used for subsequent fractionation and immunochemical study. Comparison of both results demonstrate the ability of these cathepsins to degrade a basement membrane at near neutral pH values. The differences observed in the size and the number of fragments suggest that the three proteinases exhibit similar specificities in basement membrane digestion, as shown previously. Nevertheless, cathepsin L seems to be more effective than cathepsins B and B-like. From this study, cysteine proteinases could be associated to basement membrane destruction. Soluble cysteine proteinase digests of bovine lens capsules showed several bands of gelatinolytic activity by gelatin zymography. Three major bands of 77, 60 and 45 kDa were seen whatever the cysteine proteinase used. These bands were identified as fibronectin fragments. Thus cysteine proteinases can activate the latent proteinase fibronectin from basement membrane leading to a new "metastatic cascade". This would be an important factor in the "in vivo" basement membrane dissolution observed during tumor invasion.

In vitro activation of pro-cathepsin B by three serine proteinases: leucocyte elastase, cathepsin G, and the urokinase-type plasminogen activator

In vitro activation of pro-cathepsin B purified from ascitic fluid of ovarian carcinomas by serine proteinases was studied. Both elastase and cathepsin G from human leucocytes were found to be activators, on the basis of generation of cathepsin B activity and processing of the precursor. These results represent a new cooperative pathway between cancer cells and host cells. The urokinase-type plasminogen activator activated pro-cathepsin B faster than leucocyte proteinases. A new relationship is emerging between the cysteine proteinases and the plasmin-activation system. Both pathways suggest an important role of cathepsin B in the proteolytic cascade associated with tumour invasion.

Survival differences and trends in patients with AIDS in the United States

The AIDS surveillance system maintained by the Centers for Disease Control and Prevention (CDC) provides a unique data base for estimating survival after a diagnosis of AIDS for the general AIDS population in the United States. Because patients enrolled in most AIDS clinical trial studies receive unusual medical care that may not be available to the general public and typically have relatively longer survival time, estimates obtained from these studies may not be of direct use in assessing the national health-care needs. Furthermore, such studies are usually of short duration and may not be very informative for long-term health-policy planning. We present survival estimates obtained from the CDC surveillance data for the adult/adolescent AIDS population in the United States and compare their survival and trend in survival on gender, sexual behavior, and injection-drug use status. These estimates provide information for mortality risk after an AIDS diagnosis over a period of 8 years and for trend of survival during the period between 1983 and 1991.

Age at AIDS diagnosis for children with perinatally acquired HIV

The human immunodeficiency virus (HIV) can be transmitted from mother to child in utero, during birth, or after birth through breast milk. While the majority of children born to HIV-positive mothers are not infected, almost all carry maternal antibodies. The number of maternal or perinatal exposures can be determined by screening all newborns for these antibodies, while maintaining the anonymity of mother and child. Combining newborn screening results with traditional surveillance data from New York City, we estimate that among maternally infected children, almost 14% will be diagnosed in the 1st year of life and, approximately 11-12% each year after, through age 7. This implies a median diagnosis age of 4.1 years, and suggests that in the majority of infected children, AIDS will not develop until after the 1st few years of life. We also examine the diagnosis age distribution for all children (infected and not) with a positive screen. We conclude that by approximately 7 years of age, 17% of children who test positive will be diagnosed with clinical AIDS, according to a yearly rate of > 2%. Based on these results, the perinatally acquired pediatric epidemic can be projected from the newborn screening data.

Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells

Estradiol stimulates protein phosphorylation on tyrosine in human breast cancer MCF-7 cells under conditions of estradiol-stimulated cell growth. The stimulatory effect of estradiol has been observed by 32P-labeling of cells followed by purification of proteins using antiphosphotyrosine antibody coupled to agarose and confirmed by immunoblotting analysis with antiphosphotyrosine antibody. This stimulation is immediate (maximal in 10 s) and transient. In addition, it is receptor-mediated since estradiol stimulation is prevented by two well-known antiestrogens, OH-Tamoxifen and ICI 164,384. Estradiol fails to stimulate tyrosine protein phosphorylation of Cos cells which do not express the estradiol receptor. Two substrates of the estrogen stimulated phosphorylation on tyrosine with approximate mol wt of 55 and 60 kDa interact with a polyclonal antibody raised against amino acids 527-533 of pp60c-src (anti-cst.1 antibody). Tyrosine kinase activity of immunoprecipitates made using either anti cst.1 antibody or the monoclonal 327 antibody specific for pp60c-src shows that kinase(s) strongly related to pp60c-src are immediately and transiently stimulated by estradiol treatment of cells. The present findings provide the first demonstration that a steroid hormone rapidly stimulates tyrosine phosphorylation of target cells and induces functional modifications of substrates of this phosphorylation. These modifications might initiate the estradiol action on cell growth.

Generation of matrix-degrading proteolytic system from fibronectin by cathepsins B, G, H and L

By their endoproteinase activities, cathepsins B, G, H and L can generate matrix-degrading proteolytic system from fibronectin. All four cathepsins studied cleaved fibronectin in fragments that were either proteolytically active or activated after incubation at pH 7.4 and in the presence of Ca2+. The highest enhancement of the matrix protein-degrading activity was observed after a gelatin-affinity chromatography of each digest. These results suggest that the effect of cathepsins at physiological pH in vivo may be enhanced by the activation of a matrix-degrading proteolytic system from fibronectin.

Antenatal corticosteroids appear to reduce the risk of postnatal germinal matrix hemorrhage in intubated low birth weight newborns

OBJECTIVE

To determine to what extent the reduced risk in preterm newborns of intracranial hemorrhage attributed to antenatal corticosteroids (ANCS) reflects reductions in the incidence of respiratory distress and its correlates.

METHODS

In a sample of 239 very low birth weight newborns recruited for a clinical trial of phenobarbital prophylaxis of subependymal/intraventricular hemorrhage, we explored the relationship between ANCS, the occurrence of germinal matrix hemorrhage (GMH) that first became evident after the 12th postnatal hour, and putative intervening variables such as acidosis, elevated peak inspiratory pressure, pneumothorax-pulmonary interstitial emphysema, and elevated continuous positive airway pressure.

RESULTS

In multivariate models adjusting for confounders, newborns exposed to ANCS were at approximately one third the risk of GMH experienced by newborns not exposed to a full course of ANCS. The additions of measures and correlates of respiratory distress severity to these models did not change the GMH risk associated with ANCS.

CONCLUSION

The GMH-protective effect of ANCS does not appear to be a consequence of enhanced pulmonary maturation.

Cyclin D1 is a nuclear protein required for cell cycle progression in G1

A cascade of events is triggered upon the addition of growth factor to quiescent mammalian cells, which ultimately restarts proliferation by inducing the transition from G0/G1 to S-phase. We have studied cyclin D1, a putative G1 cyclin, in normal diploid human fibroblasts. Cyclin D1 accumulated and reached a maximum level before S-phase upon the addition of serum to quiescent cells. The protein was localized to the nucleus, and it disappeared from the nucleus as cells proceeded into S-phase. Microinjection of anti-cyclin D1 antibodies or antisense plasmid prevented cells from entering S-phase, and the kinetics of inhibition showed that cyclin D1 is required at a point in the cell cycle earlier than cyclin A. These results demonstrate that cyclin D1 is a critical target of proliferative signals in G1.

Differential modulation of cyclin gene expression by MYC

We have investigated the effects of deregulated expression of the human c-MYC protooncogene on cyclin gene expression and on the transcription factor E2F. We found that constitutive expression of MYC or activation of conditional MycER chimeras led to higher levels of cyclin A and cyclin E mRNA. Activation of cyclin A expression by MYC led to a growth factor-independent association of cyclin A and cdk2 with the transcription factor E2F and correlated with an increase in E2F transcriptional activity. In contrast, expression of the G1 phase cyclin D1 was strongly reduced in MYC-transformed cells. In synchronized cells, repression of cyclin D1 by MYC occurred very early in the G1 phase of the cell cycle.

G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently

We investigated the temporal regulation of cyclin A- and B1-dependent kinases in human lymphoma cells treated with nitrogen mustard (HN2) and pentoxifylline, to determine whether the activity of these complexes correlated with cell cycle arrest induced by DNA damage. Cells were synchronized in G1/S, treated with HN2, and then postincubated with pentoxifylline. HN2-induced a protracted delay in G2 phase. This delay correlated with suppression of cyclin B1- and cdc2-kinase activities, and stabilization of hyperphosphorylated-cdc2 in the presence of similar cyclin B1 levels to those found in mitosis. HN2 had no discernible effect on the S phase activity of cyclin A- or cdk2-immune complexes. Entry of control cells into mitosis correlated with destruction of cyclin A, disappearance of cyclin A-bound cdk2 and decreased cdk2 kinase activity. G2 delay induced by HN2 was associated with stabilization of cyclin A, increased abundance of cyclin A-bound cdk2, and increased cdk2 activity. Cyclin A was also associated with cdc2, which, contrary to complexes containing cdk2, were only activated upon entry into mitosis. Pentoxifylline abrogated cell cycle arrest induced by aphidicolin and HN2 in human lymphoma cells. Pentoxifylline also reverted the activity of cyclin A- and B1-kinases in HN2-treated cells to approximately that observed in controls. Our findings suggest that delayed entry into mitosis following DNA damage correlates with suppression of cyclin B1/cdc2 and cyclin A/cdc2 complexes, while maintaining cyclin A/cdc2 complexes in an active state. Furthermore, we found that pentoxifylline disrupts the signal transduction pathway that regulates these complexes when damaged DNA is present, resulting in abrogation of cell cycle arrest.

Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts

In mammalian cells inhibition of the cdc2 function results in arrest in the G2-phase of the cell cycle. Several cdc2-related gene products have been identified recently and it has been hypothesized that they control earlier cell cycle events. Here we have studied the relationship between activation of one of these cdc2 homologs, the cdk2 protein kinase, and the progression through the cell cycle in cultured human fibroblasts. We found that cdk2 was activated and specifically localized to the nucleus during S phase and G2. Microinjection of affinity-purified anti-cdk2 antibodies but not of affinity-purified anti-cdc2 antibodies, during G1, inhibited entry into S phase. The specificity of these effects was demonstrated by the fact that a plasmid-driven cdk2 overexpression counteracted the inhibition. These results demonstrate that the cdk2 protein kinase is involved in the activation of DNA synthesis.